Some specific driver genetic mutations have been identified in NSCLC, such as EGFR [13,14], EML4-ALK fusion gene [15] and ROS fusion gene [16], which direct the development of anti-cancer drugs towards to molecular-targeted therapy, by specifically targeting these driver mutations for individualized treatment purpose. This evidence concerns the gene EGFR and non-small cell lung carcinoma.